Development of integrated pest management for sugarcane borer, Diatraea saccharalis in rice

Rice is grown over an area of approximately 500,000 acres in Louisiana. The lepidopteran stem borer complex attacking rice in the southern U.S includes stalk borer Chilo plejadellus Zincken, sugarcane borer (SCB) Diatraea saccharalis (F.) and Mexican rice borer, Eoreuma loftini Dyar. With the increasing impact of stem borers in Louisiana, an urgent need exists to develop strategies for management. Currently, no IPM program is in place for stem borers in Louisiana rice and research has been initiated to develop an IPM program for these pests. The first objective of this research was focused on host plant resistance. For this objective, oviposition preference and larval performance of sugarcane borer on commonly grown rice cultivars in Louisiana were investigated. Results from the oviposition preference study revealed significant differences among cultivars. Overall females of D. saccharalis preferred ovipositing on the upper sides of the leaves of rice plants. In the performance study, three different measures of performance were used. Results from these studies revealed significant differences among varieties for these measures of performance. Results also revealed a strong correlation between different measures of performance as well as between performance and preference. Results from the compensation study revealed differences in compensatory response of same eight cultivars. In the silicon soil amendment study, a significant increase in silicon content of rice plants supplemented with calcium silicate was observed compared to the control plants. Soil Si amendment led to lower relative growth rates and reduced boring success of sugarcane borer larvae on. Studies were conducted to evaluate the efficacy of Dermacor seed treatment against sugarcane borer. Dermacor seed treatment was the most effective among different insecticides used in a field study and significantly increased larval mortality in lab and greenhouse experiments. These studies will help facilitate scouting for sugarcane borer in the field and improvement in insecticide timing. Potential exists for current use of these (moderately resistant) cultivars in IPM programs and as sources of resistance in breeding programs for stem borer resistance. Soil Si amendment and Dermacor seed treatments has the potential to fit into the IPM program

ASCORBIC ACID AS A GROWTH ADJUVANT IN ENCAPSULATED PROTOCORM-LIKE-BODIES OF RHYNCHOSTYLIS RETUSA BL. (ORCHIDACEAE)

In the present study, effect of ascorbic acid, a known growth adjuvant on encapsulated protocorm-like-bodies (PLBs) of Rhynchostylis retusa Bl. was investigated. PLBs were encapsulated in calcium alginate (3.5% sodium alginate and 100mM calcium chloride) prepared in Mitra et al. (1976) basal medium and supplemented with different concentration of ascorbic acid (5, 10, 15, 20mM). The encapsulated PLBs were stored at 25°C. Their germination response and germination potential was evaluated after every 4 weeks on basal media. Control set of encapsulated PLBs, failed to germinate after 32 weeks. However, PLBs with 15mM ascorbic acid in the encapsulated matrix showed the best response; nearly 90% germinated even after 32 weeks of storage. The survival and germination frequency was directly proportional to the level of ascorbic acid in the alginate mix upto 15mM level but declined on further increase. Differentiation of PLBs into plantlet was better in synthetic seeds containing lower concentration of ascorbic acid (5mM) as compared to higher levels (15, 20mM) whereas multiplication of secondary PLBs was more pronounced at higher levels. Chlorophyll content was inversely proportional to the level of ascorbic acid in the nutrient mix; lush green PLBs were observed at low concentration of ascorbic acid (5mM). This study highlights the potential of ascorbic acid as an aid to growth and survival of encapsulated PLBs upon storage

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Background: Future trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050. Methods: Using forecasts of major drivers of health such as the Socio-demographic Index (SDI; a composite measure of lag-distributed income per capita, mean years of education, and total fertility under 25 years of age) and the full set of risk factor exposures captured by GBD, we provide cause-specific forecasts of mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) by age and sex from 2022 to 2050 for 204 countries and territories, 21 GBD regions, seven super-regions, and the world. All analyses were done at the cause-specific level so that only risk factors deemed causal by the GBD comparative risk assessment influenced future trajectories of mortality for each disease. Cause-specific mortality was modelled using mixed-effects models with SDI and time as the main covariates, and the combined impact of causal risk factors as an offset in the model. At the all-cause mortality level, we captured unexplained variation by modelling residuals with an autoregressive integrated moving average model with drift attenuation. These all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models, thus ensuring a robust estimate of cause-specific mortality. For non-fatal measures (eg, low back pain), incidence and prevalence were forecasted from mixed-effects models with SDI as the main covariate, and YLDs were computed from the resulting prevalence forecasts and average disability weights from GBD. Alternative future scenarios were constructed by replacing appropriate reference trajectories for risk factors with hypothetical trajectories of gradual elimination of risk factor exposure from current levels to 2050. The scenarios were constructed from various sets of risk factors: environmental risks (Safer Environment scenario), risks associated with communicable, maternal, neonatal, and nutritional diseases (CMNNs; Improved Childhood Nutrition and Vaccination scenario), risks associated with major non-communicable diseases (NCDs; Improved Behavioural and Metabolic Risks scenario), and the combined effects of these three scenarios. Using the Shared Socioeconomic Pathways climate scenarios SSP2-4.5 as reference and SSP1-1.9 as an optimistic alternative in the Safer Environment scenario, we accounted for climate change impact on health by using the most recent Intergovernmental Panel on Climate Change temperature forecasts and published trajectories of ambient air pollution for the same two scenarios. Life expectancy and healthy life expectancy were computed using standard methods. The forecasting framework includes computing the age-sex-specific future population for each location and separately for each scenario. 95% uncertainty intervals (UIs) for each individual future estimate were derived from the 2·5th and 97·5th percentiles of distributions generated from propagating 500 draws through the multistage computational pipeline. Findings: In the reference scenario forecast, global and super-regional life expectancy increased from 2022 to 2050, but improvement was at a slower pace than in the three decades preceding the COVID-19 pandemic (beginning in 2020). Gains in future life expectancy were forecasted to be greatest in super-regions with comparatively low life expectancies (such as sub-Saharan Africa) compared with super-regions with higher life expectancies (such as the high-income super-region), leading to a trend towards convergence in life expectancy across locations between now and 2050. At the super-region level, forecasted healthy life expectancy patterns were similar to those of life expectancies. Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. We also forecasted that both DALY counts and age-standardised DALY rates will continue to shift from CMNNs to NCDs, with the most pronounced shifts occurring in sub-Saharan Africa (60·1% [95% UI 56·8–63·1] of DALYs were from CMNNs in 2022 compared with 35·8% [31·0–45·0] in 2050) and south Asia (31·7% [29·2–34·1] to 15·5% [13·7–17·5]). This shift is reflected in the leading global causes of DALYs, with the top four causes in 2050 being ischaemic heart disease, stroke, diabetes, and chronic obstructive pulmonary disease, compared with 2022, with ischaemic heart disease, neonatal disorders, stroke, and lower respiratory infections at the top. The global proportion of DALYs due to YLDs likewise increased from 33·8% (27·4–40·3) to 41·1% (33·9–48·1) from 2022 to 2050, demonstrating an important shift in overall disease burden towards morbidity and away from premature death. The largest shift of this kind was forecasted for sub-Saharan Africa, from 20·1% (15·6–25·3) of DALYs due to YLDs in 2022 to 35·6% (26·5–43·0) in 2050. In the assessment of alternative future scenarios, the combined effects of the scenarios (Safer Environment, Improved Childhood Nutrition and Vaccination, and Improved Behavioural and Metabolic Risks scenarios) demonstrated an important decrease in the global burden of DALYs in 2050 of 15·4% (13·5–17·5) compared with the reference scenario, with decreases across super-regions ranging from 10·4% (9·7–11·3) in the high-income super-region to 23·9% (20·7–27·3) in north Africa and the Middle East. The Safer Environment scenario had its largest decrease in sub-Saharan Africa (5·2% [3·5–6·8]), the Improved Behavioural and Metabolic Risks scenario in north Africa and the Middle East (23·2% [20·2–26·5]), and the Improved Nutrition and Vaccination scenario in sub-Saharan Africa (2·0% [–0·6 to 3·6]). Interpretation: Globally, life expectancy and age-standardised disease burden were forecasted to improve between 2022 and 2050, with the majority of the burden continuing to shift from CMNNs to NCDs. That said, continued progress on reducing the CMNN disease burden will be dependent on maintaining investment in and policy emphasis on CMNN disease prevention and treatment. Mostly due to growth and ageing of populations, the number of deaths and DALYs due to all causes combined will generally increase. By constructing alternative future scenarios wherein certain risk exposures are eliminated by 2050, we have shown that opportunities exist to substantially improve health outcomes in the future through concerted efforts to prevent exposure to well established risk factors and to expand access to key health interventions

PHYSICOCHEMICAL STUDY OF THERMOPLASTIC STARCH(TPS) USING IONIC LIQUID AS PLASTICIZER

This research investigates the physicochemical and hygroscopic properties of thermoplastic starch (TPS) an alternative biodegradable material. The material is formed from starch, Ionic liquid (IL) as plasticizer and rice straw fibre (RS) as fillers. TPS is synthesised through starch gelatinization process with the presence of plasticizer at elevated temperature. For this study, two types of ionic liquids as plasticizer are compared which are 1-ethyl-3-methylimidazolium acetate [Emim]Ac and 1-ethyl-3-methylimidazolium chloride [Emim]Cl. The best plasticizer will be chosen through thermal analysis by using Differential Scanning Calorimetry (DSC) and Thermal Gravimetric Analysis (TGA). From the result, it was found that [Emim]Ac was the better plasticizer. Following towards the second focus of this study which is to investigate the physicochemical properties and the moisture absorption rate of the synthesised TPS. The optimised TPS will be mixed with RS which aims to reduce moisture uptake. From the moisture absorption analysis, it was found that, 40% of RS loading showed the lowest moisture absorption rate for both 50% and 75% relative humidity (RH). Whereas, the FTIR results indicated that there is new bond formation in the synthesised TPS as well as TPS mixed with RS. SEM images clearly shows the interaction between the TPS samples. In addition, the TPS that is formed is more amorphous compared to other samples. The thermal analysis, showed that the TPS synthesised is thermally stable which includes TPS with 40% RS loading. The biodegradability test also proved that indeed [Emim]Ac can withstand microbial attack. The results obtained clearly showed there is a good potential to use [Emim] Ac and RS as plasticizer and fillers respectively to synthesise an alternative biodegradable material

PHYSICOCHEMICAL STUDY OF THERMOPLASTIC STARCH(TPS) USING IONIC LIQUID AS PLASTICIZER

This research investigates the physicochemical and hygroscopic properties of thermoplastic starch (TPS) an alternative biodegradable material. The material is formed from starch, Ionic liquid (IL) as plasticizer and rice straw fibre (RS) as fillers. TPS is synthesised through starch gelatinization process with the presence of plasticizer at elevated temperature. For this study, two types of ionic liquids as plasticizer are compared which are 1-ethyl-3-methylimidazolium acetate [Emim]Ac and 1-ethyl-3-methylimidazolium chloride [Emim]Cl. The best plasticizer will be chosen through thermal analysis by using Differential Scanning Calorimetry (DSC) and Thermal Gravimetric Analysis (TGA). From the result, it was found that [Emim]Ac was the better plasticizer. Following towards the second focus of this study which is to investigate the physicochemical properties and the moisture absorption rate of the synthesised TPS. The optimised TPS will be mixed with RS which aims to reduce moisture uptake. From the moisture absorption analysis, it was found that, 40% of RS loading showed the lowest moisture absorption rate for both 50% and 75% relative humidity (RH). Whereas, the FTIR results indicated that there is new bond formation in the synthesised TPS as well as TPS mixed with RS. SEM images clearly shows the interaction between the TPS samples. In addition, the TPS that is formed is more amorphous compared to other samples. The thermal analysis, showed that the TPS synthesised is thermally stable which includes TPS with 40% RS loading. The biodegradability test also proved that indeed [Emim]Ac can withstand microbial attack. The results obtained clearly showed there is a good potential to use [Emim] Ac and RS as plasticizer and fillers respectively to synthesise an alternative biodegradable material

Orthodontic extrusion of subgingivally fractured lateral incisor and canine using gold post: A case report: 1 year follow-up

The case report describes a multidisciplinary approach using orthodontic forced eruption to facilitate prosthetic restoration of a maxillary permanent lateral incisor and canine with poor restorability for a young patient. Restoration after orthodontic eruption presents a more conservative treatment choice in young patients compared with prosthetic restoration after extraction. On examination, the patient had root stumps in the region of 22 and 23. We decided to treat the patient by orthodontic extrusion followed by endodontic post and core. The case was treated with the help of 19 gauge wire and gold posts

Head-to-head comparison of tazarotene and calcitriol with or without sequential therapy in mild-to-moderate psoriasis: A randomized open-label study

Objective: Psoriasis is an autoimmune disease that causes rapid turnover of skin cells. It is a chronic disease that affects a patient's quality of life significantly and frequently requires long-term treatment. The study on sequential therapy with tazarotene 0.1% and calcitriol 0.0003% has not been tried so far; hence, we designed this study to compare the safety and efficacy of sequential therapy with tazarotene 0.1% cream and calcitriol 0.0003% ointment versus monotherapy in mild-to-moderate stable plaque psoriasis (SPP). The objective of this study was to compare the safety and efficacy of topical sequential treatment with tazarotene followed by calcitriol, topical calcitriol followed by tazarotene, tazarotene monotherapy, calcitriol monotherapy, and compare the safety and efficacy of the sequential therapies with monotherapies. Methods: The study was a single center, prospective parallel-group, active control, randomized study of 16 weeks duration (treatment for 8 weeks and follow-up for 16 weeks), randomized to either of the four groups, i.e., tazarotene 0.1% for 4 weeks followed by calcitriol 0.0003% for 4 weeks or calcitriol 0.0003% for 4 weeks followed by tazarotene 0.1% for 4 weeks or tazarotene 0.1% for 8 weeks or calcitriol 0.0003% for 8 weeks. Both tazarotene and calcitriol were applied once daily in all the groups. Findings: There was no significant difference with regard to age and duration of illness among the four treatment groups. Statistically significant improvement was observed in erythema, scaling, and induration scores, and Physician's global assessment scale at 8 weeks and 16 weeks as compared to baseline in tazarotene – calcitriol, calcitriol – tazarotene, and calcitriol versus tazarotene groups. Conclusion: This study concluded that topical treatment with tazarotene 0.1% and calcitriol 0.003% was efficacious in treating mild-to-moderate SPP as both sequential and monotherapy. However, topical treatment with tazarotene as monotherapy was the least efficacious

Adverse drug reactions in psychiatry outpatient department of a tertiary care hospital in Western Uttar Pradesh: An observational study

Objective: Psychiatric disorders are chronic in nature which require medications for a long duration. These medications have been associated with many adverse events. Failure to recognize an adverse drug reaction (ADR) exposes the patient to continuing risk of ADR, leading to a significant impact on patient's quality of life. Thus, the present study carried out to identify the pattern of ADRs reported due to psychotropic medication. Methods: This was a cross-sectional study conducted to analyze ADRs reported from the psychiatry department of a tertiary care teaching hospital from October 2021 to March 2022. Findings: A total of 137 ADRs were identified from 102 patients. Majority of the ADRs were reported from antidepressants, with paroxetine being the leading offending drug. The central nervous system was most commonly affected, and dizziness (13.13%) was the most common ADR noted. On causality assessment, 97 ADRs (70.8%) were of “possible” type. Almost half of the patients with ADRs (47.5%) recovered spontaneously. No ADR encountered turned out to be fatal. Conclusion: The present study revealed that the majority of ADRs reported from psychiatry OPD were mild in nature. We reinforce the identification of ADR is crucial in the hospital setting process as it gives an insight into the risk-benefit ratio for rational use of the drug

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

BackgroundFuture trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050.MethodsUsing forecasts of major drivers of health such as the Socio-demographic Index (SDI; a composite measure of lag-distributed income per capita, mean years of education, and total fertility under 25 years of age) and the full set of risk factor exposures captured by GBD, we provide cause-specific forecasts of mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) by age and sex from 2022 to 2050 for 204 countries and territories, 21 GBD regions, seven super-regions, and the world. All analyses were done at the cause-specific level so that only risk factors deemed causal by the GBD comparative risk assessment influenced future trajectories of mortality for each disease. Cause-specific mortality was modelled using mixed-effects models with SDI and time as the main covariates, and the combined impact of causal risk factors as an offset in the model. At the all-cause mortality level, we captured unexplained variation by modelling residuals with an autoregressive integrated moving average model with drift attenuation. These all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models, thus ensuring a robust estimate of cause-specific mortality. For non-fatal measures (eg, low back pain), incidence and prevalence were forecasted from mixed-effects models with SDI as the main covariate, and YLDs were computed from the resulting prevalence forecasts and average disability weights from GBD. Alternative future scenarios were constructed by replacing appropriate reference trajectories for risk factors with hypothetical trajectories of gradual elimination of risk factor exposure from current levels to 2050. The scenarios were constructed from various sets of risk factors: environmental risks (Safer Environment scenario), risks associated with communicable, maternal, neonatal, and nutritional diseases (CMNNs; Improved Childhood Nutrition and Vaccination scenario), risks associated with major non-communicable diseases (NCDs; Improved Behavioural and Metabolic Risks scenario), and the combined effects of these three scenarios. Using the Shared Socioeconomic Pathways climate scenarios SSP2-4.5 as reference and SSP1-1.9 as an optimistic alternative in the Safer Environment scenario, we accounted for climate change impact on health by using the most recent Intergovernmental Panel on Climate Change temperature forecasts and published trajectories of ambient air pollution for the same two scenarios. Life expectancy and healthy life expectancy were computed using standard methods. The forecasting framework includes computing the age-sex-specific future population for each location and separately for each scenario. 95% uncertainty intervals (UIs) for each individual future estimate were derived from the 2·5th and 97·5th percentiles of distributions generated from propagating 500 draws through the multistage computational pipeline.FindingsIn the reference scenario forecast, global and super-regional life expectancy increased from 2022 to 2050, but improvement was at a slower pace than in the three decades preceding the COVID-19 pandemic (beginning in 2020). Gains in future life expectancy were forecasted to be greatest in super-regions with comparatively low life expectancies (such as sub-Saharan Africa) compared with super-regions with higher life expectancies (such as the high-income super-region), leading to a trend towards convergence in life expectancy across locations between now and 2050. At the super-region level, forecasted healthy life expectancy patterns were similar to those of life expectancies. Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. We also forecasted that both DALY counts and age-standardised DALY rates will continue to shift from CMNNs to NCDs, with the most pronounced shifts occurring in sub-Saharan Africa (60·1% [95% UI 56·8–63·1] of DALYs were from CMNNs in 2022 compared with 35·8% [31·0–45·0] in 2050) and south Asia (31·7% [29·2–34·1] to 15·5% [13·7–17·5]). This shift is reflected in the leading global causes of DALYs, with the top four causes in 2050 being ischaemic heart disease, stroke, diabetes, and chronic obstructive pulmonary disease, compared with 2022, with ischaemic heart disease, neonatal disorders, stroke, and lower respiratory infections at the top. The global proportion of DALYs due to YLDs likewise increased from 33·8% (27·4–40·3) to 41·1% (33·9–48·1) from 2022 to 2050, demonstrating an important shift in overall disease burden towards morbidity and away from premature death. The largest shift of this kind was forecasted for sub-Saharan Africa, from 20·1% (15·6–25·3) of DALYs due to YLDs in 2022 to 35·6% (26·5–43·0) in 2050. In the assessment of alternative future scenarios, the combined effects of the scenarios (Safer Environment, Improved Childhood Nutrition and Vaccination, and Improved Behavioural and Metabolic Risks scenarios) demonstrated an important decrease in the global burden of DALYs in 2050 of 15·4% (13·5–17·5) compared with the reference scenario, with decreases across super-regions ranging from 10·4% (9·7–11·3) in the high-income super-region to 23·9% (20·7–27·3) in north Africa and the Middle East. The Safer Environment scenario had its largest decrease in sub-Saharan Africa (5·2% [3·5–6·8]), the Improved Behavioural and Metabolic Risks scenario in north Africa and the Middle East (23·2% [20·2–26·5]), and the Improved Nutrition and Vaccination scenario in sub-Saharan Africa (2·0% [–0·6 to 3·6]).InterpretationGlobally, life expectancy and age-standardised disease burden were forecasted to improve between 2022 and 2050, with the majority of the burden continuing to shift from CMNNs to NCDs. That said, continued progress on reducing the CMNN disease burden will be dependent on maintaining investment in and policy emphasis on CMNN disease prevention and treatment. Mostly due to growth and ageing of populations, the number of deaths and DALYs due to all causes combined will generally increase. By constructing alternative future scenarios wherein certain risk exposures are eliminated by 2050, we have shown that opportunities exist to substantially improve health outcomes in the future through concerted efforts to prevent exposure to well established risk factors and to expand access to key health interventions.FundingBill & Melinda Gates Foundation.</p